These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 31203802)

  • 1. Liraglutide as Adjunct to Insulin Treatment in Patients with Type 1 Diabetes: A Systematic Review and Meta-analysis.
    Dimitrios P; Michael D; Vasilios K; Konstantinos S; Konstantinos I; Ioanna Z; Konstantinos P; Spyridon B; Asterios K
    Curr Diabetes Rev; 2020; 16(4):313-326. PubMed ID: 31203802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liraglutide in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials.
    Kalogirou MS; Patoulias D; Haidich AB; Akriviadis E; Sinakos E
    Clin Res Hepatol Gastroenterol; 2021 May; 45(3):101568. PubMed ID: 33309563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the ADJUNCT ONE and ADJUNCT TWO randomized controlled trials.
    Dejgaard TF; von Scholten BJ; Christiansen E; Kreiner FF; Bardtrum L; von Herrath M; Mathieu C; Madsbad S;
    Diabetes Obes Metab; 2021 Dec; 23(12):2752-2762. PubMed ID: 34463425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study.
    Frandsen CS; Dejgaard TF; Holst JJ; Andersen HU; Thorsteinsson B; Madsbad S
    Diabetes Care; 2015 Dec; 38(12):2250-7. PubMed ID: 26486191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addition of Liraglutide to Insulin in Patients With Type 1 Diabetes: A Randomized Placebo-Controlled Clinical Trial of 12 Weeks.
    Kuhadiya ND; Dhindsa S; Ghanim H; Mehta A; Makdissi A; Batra M; Sandhu S; Hejna J; Green K; Bellini N; Yang M; Chaudhuri A; Dandona P
    Diabetes Care; 2016 Jun; 39(6):1027-35. PubMed ID: 27208343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liraglutide for treating type 1 diabetes.
    Dejgaard TF; Frandsen CS; Holst JJ; Madsbad S
    Expert Opin Biol Ther; 2016; 16(4):579-90. PubMed ID: 26926662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucagon-Like Peptide 1 Analogues as Adjunctive Therapy for Patients With Type 1 Diabetes: An Updated Systematic Review and Meta-analysis.
    Park J; Ntelis S; Yunasan E; Downton KD; Yip TC; Munir KM; Haq N
    J Clin Endocrinol Metab; 2023 Dec; 109(1):279-292. PubMed ID: 37561012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic Properties of Liraglutide as Adjunct to Insulin in Subjects with Type 1 Diabetes Mellitus.
    Mader JK; Jensen L; Ingwersen SH; Christiansen E; Heller S; Pieber TR
    Clin Pharmacokinet; 2016 Nov; 55(11):1457-1463. PubMed ID: 27282158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes--a protocol for a randomised, double-blind, placebo-controlled study: the Lira-1 study.
    Dejgaard TF; Knop FK; Tarnow L; Frandsen CS; Hansen TS; Almdal T; Holst JJ; Madsbad S; Andersen HU
    BMJ Open; 2015 Apr; 5(4):e007791. PubMed ID: 25838513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus.
    Guyton J; Jeon M; Brooks A
    Am J Health Syst Pharm; 2019 Oct; 76(21):1739-1748. PubMed ID: 31612934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta-analysis.
    Sun F; Chai S; Li L; Yu K; Yang Z; Wu S; Zhang Y; Ji L; Zhan S
    J Diabetes Res; 2015; 2015():157201. PubMed ID: 25688373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of liraglutide in type 2 diabetes mellitus patients complicated with coronary artery disease: A systematic review and meta-analysis of randomized controlled trials.
    Wang L; Xin Q; Wang Y; Chen Z; Yuan R; Miao Y; Zhang G; Cong W
    Pharmacol Res; 2021 Sep; 171():105765. PubMed ID: 34252552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis.
    Sun F; Wu S; Guo S; Yu K; Yang Z; Li L; Zhang Y; Quan X; Ji L; Zhan S
    Diabetes Res Clin Pract; 2015 Oct; 110(1):26-37. PubMed ID: 26358202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of glucagon-like peptide-1 receptor agonists on lipid profiles among type 2 diabetes: a systematic review and network meta-analysis.
    Sun F; Wu S; Wang J; Guo S; Chai S; Yang Z; Li L; Zhang Y; Ji L; Zhan S
    Clin Ther; 2015 Jan; 37(1):225-241.e8. PubMed ID: 25554560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of teplizumab in the treatment of type 1 diabetes mellitus: An updated systematic review and meta-analysis of randomized controlled trials.
    Grando Alves G; Cunha L; Henkes Machado R; Lins de Menezes V
    Diabetes Obes Metab; 2024 Jul; 26(7):2652-2661. PubMed ID: 38602411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials.
    Patoulias D; Stavropoulos K; Imprialos K; Katsimardou A; Kalogirou MS; Koutsampasopoulos K; Zografou I; Papadopoulos C; Karagiannis A; Doumas M
    Diabetes Res Clin Pract; 2019 Dec; 158():107927. PubMed ID: 31733280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Durable efficacy of liraglutide in patients with type 2 diabetes and pronounced insulin-associated weight gain: 52-week results from the Effect of Liraglutide on insulin-associated wEight GAiN in patients with Type 2 diabetes' (ELEGANT) randomized controlled trial.
    de Wit HM; Vervoort GM; Jansen HJ; de Galan BE; Tack CJ
    J Intern Med; 2016 Mar; 279(3):283-92. PubMed ID: 26553486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials.
    Monami M; Marchionni N; Mannucci E
    Eur J Endocrinol; 2009 Jun; 160(6):909-17. PubMed ID: 19318378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
    Montanya E; Sesti G
    Clin Ther; 2009 Nov; 31(11):2472-88. PubMed ID: 20109994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liraglutide acutely suppresses glucagon, lipolysis and ketogenesis in type 1 diabetes.
    Garg M; Ghanim H; Kuhadiya ND; Green K; Hejna J; Abuaysheh S; Torre B; Batra M; Makdissi A; Chaudhuri A; Dandona P
    Diabetes Obes Metab; 2017 Sep; 19(9):1306-1311. PubMed ID: 28304146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.